WELCOME at the dexdor (dexmedetomidine) website by Orion Pharma

Critical care, including ICU-sedation and patient-centered management of pain, agitation and delirium, is one of the key expertise areas of Orion Pharma.

This website is aimed for health care professionals who can find detailed information about dexdor (dexmedetomidine). If you are not a health care professional, please consult one for further information. If you are a health care professional, please log in/register.

About dexdor (dexmedetomidine)

Dexdor (dexmedetomidine) is indicated to use for sedation of adult Intensive Care Unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3). 

Dexdor (dexmedetomidine) is contraindicated in hypersensitivity to the active substance or to any of the excipients, in advanced heart block (grade 2 or 3) unless paced, in uncontrolled hypotension, in acute cerebrovascular conditions.

Dexdor (dexmedetomidine) is for hospital use only, it should be administered by healthcare professionals skilled in the management of patients requiring intensive care.

Reference information, dexdor (dexmedetomidine)

Link to the Summary of Product Characteristics and to the Package leaflet: Information for the user, Dexdor (dexmedetomidine)

Link to the European Public Assessment Report, Dexdor (dexmedetomidine) 





Featured lecture videos from latest European critical care congresses, patient videos, downloadable materials and more. Login is required to enter this section.


Insights from European critical care congressesLatest live webcast was sent from 38th ISICEM. Recordings are now published on this site. Login is required to enter this section.

Dexmedetomidine in adult ICU